The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.

The firm reported positive results this week from a biomarker analysis in a Phase IIb trial of OST-HER2, which it will submit to regulators.

The announcement comes on the heels of promising preliminary Phase II data, in which OCU410 reduced lesion growth in patients' eyes.

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...

The company has started enrolling patients into a run-in period for the Phase III study, and plans to begin dosing later this ...

The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.

The partners want to develop personalized therapeutics and diagnostics based on insights derived from the Middle Eastern biorepository.

The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...

The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

The firm hopes to become a commercial-stage company this year, if the KIT inhibitor bezuclastinib is approved by the FDA as expected.

Genethon has licensed to AskBio a component of a preclinical gene therapy approach for treating Pompe disease.